SBIR-STTR Award

Rapid Assay of Cellular Immunity in Q Fever
Award last edited on: 9/13/02

Sponsored Program
SBIR
Awarding Agency
DOD : Army
Total Award Amount
$69,929
Award Phase
1
Solicitation Topic Code
A94-083
Principal Investigator
Marjorie L Wier

Company Information

Cylex Inc (AKA: Biotechnology Transfer Inc)

8980-I Old Annapolis Road
Columbia, MD 21045
   (410) 964-0236
   contact@cylex.net
   www.cylex.net
Location: Single
Congr. District: 03
County: Howard

Phase I

Contract Number: DAMD17-95-C-5057
Start Date: 3/15/95    Completed: 9/14/95
Phase I year
1995
Phase I Amount
$69,929
Cellular of T lymphocyte function is important in defense against infectious disease. T lymphocytes also participate in tumor and transplant rejection, auto immune disease, and hypersensitivity. A central facet of T lymphocyte function is activation toward proliferation following exposure to specific antigen in the conted of the major histocompatibility complex on antigen presenting cells. We proposed to develop a rapid assay based om the large and early increase in ATP in quiescent cells that are activated using Q fever as a model system. Phase I or phase II antigen from C. brunetii, the causative agent for Q fever, will be added to whole blood samples diluted in buffer. After incubation, T lymphocytes or appropriate subsets will be separated and washed by immunomagnetic beads coated with either antibody to a marker found on all T lymphocytes or to antiboldy to CD4 or CD8. The lymphocytes will be disrupted and the ATP measured by addition of luciferin/luciferase. Antigen specific response will be measured relative to a buffer control and to a T cell mitogen. The proposed method offers a rapid, simple, and sensitive alternative to standard methods of monitoring T cell function. The potendtial sensitivity of the test is based on the large increase - upto 1000 fold - of ATP in stimulated cells and the high quantum efficiency of the luciferin-luciferase reaction. The method also offers the potential to measure activation of several subsets of T lymphocytes. After a prototype assay is developed, the test will be validated against standard tests and by study of patients with Q fever.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----